

# *Additional Information*

for medical professionals

ISCADOR  AG



# Content

Integrative cancer treatment ..... 4

Mistletoe solution for injection: ISCADOR® ..... 5

Aqueous mistletoe solution for oral use:

Viscum album praeparatum ..... 10

Mistletoe cream: Viscum album

Herba Extractum resinosum 10% ..... 11

Icelandic moss solution for injection:

Cetraria praeparata ..... 12

We are here for you ..... 13



# Integrative cancer treatment

Our remedies are used in integrative oncology, supporting a therapeutic approach that focuses on each patient as an individual.

In addition to the well-known mistletoe preparation ISCADOR, we also produce other remedies, as you can see on the following pages.

More information on our preparations are available in our brochures. You can find them online in the area for medical professionals. Please note that not all of them are available in English yet, but we are working on it.

## Training courses

Interactions with experts and colleagues provide you with useful information and practical advice to treat your patients. In addition to face-to-face events, online trainings became very important over the last few years. We constantly look for new interesting opportunities and more English-speaking events.

---

*You would like to know more?*

Find more information and events in  
the professionals section of our website  
[www.iscador.com/professionals](http://www.iscador.com/professionals)

---



# Mistletoe solution for injection: ISCADOR®

Mistletoe preparations for subcutaneous injections have been part of integrative cancer treatment for many decades. Each preparation has its own characteristics and should only be applied by trained medical professionals.

ISCADOR preparations are used additionally to standard cancer treatment to improve quality of life, reduce side effects and prevent tumour recurrence. In Switzerland, they need to be prescribed by a medical professional, whereas in Germany, they are available in pharmacies. Please check the applicable rules and regulations for mistletoe preparations in your country.

## **M, P, Qu, U and A?**

The letters distinguishing our products have not been chosen randomly: They represent the host tree the mistletoe was harvested from. For more information, please consult our product brochure, or get in touch with us directly.

## **Mistletoe and its host trees**

The white-berried mistletoe (lat. *Viscum album* L.) is the most common among the more than 1000 mistletoe species worldwide. Every mistletoe is strongly influenced by its host tree and cannot exist without it. Since mistletoe is connected to the water transport system of its host tree, it absorbs the minerals dissolved in the water drawn up from the ground by each type of tree in its respective composition. As a result, mistletoes of different host trees contain different concentrations of these substances. Depending on the tumour location, you choose a preparation of a suitable host tree.

Initially, preparations from apple tree mistletoe, as well as from fir and pine were approved. Later, we expanded our product range with preparations from the rare oak and elm mistletoe (see product range overview on p. 6).

## **Metal salt additions (range may vary in different countries)**

As per Rudolf Steiner's suggestion, we also offer mistletoe preparations containing highly diluted (potentiated) metal salt additions. According to the principles of anthroposophical medicine with the intention to improve the effectiveness of the mistletoe preparation. Potentiated metal salt additions of silver, mercury and copper are used.

Our mistletoe preparations for subcutaneous injections are available in series packs containing ampoules in increasing dosage, as well as single dosage packs. The available product range may vary according to rules and regulations in each country.

### Series pack

A Series pack contains 7 ampoules of different strengths for an increasing or rhythmically varying dosage regimen to stimulate the immune system over a longer period of time. A bundle pack consists of two Series packs. A newly initiated ISCADOR therapy should always start with Series 0 to avoid overreactions.

### Sort pack

One Sort pack contains 7 ampoules of the same dosage (e.g. of ISCADOR P 1 mg) suitable for a constant dosage regimen in a palliative situation.

Spezifiziert (CH) / spezial (DE): The addition «spez.» for «spezifiziert» or «spezial» only applies to Sort packs in which all ampoules have the same strength and a standardized content of mistletoe-specific constituents.


More information on ISCADOR treatment is available in the professionals section of our website [www.iscador.com/professionals](http://www.iscador.com/professionals).



*Worldwide distribution*

Check for our international partners:  
[www.iscador.com/availability](http://www.iscador.com/availability)

---



# ISCADOR® Product Range

Fermented, aqueous mistletoe extract for subcutaneous injection

Product	2 x 7 ampoules of 1 ml			1 x 7 amp.		1 x 7 ampoules of 1 ml							
	Series 0 0,01/0,1/1 mg	Series I 0,1/1/10 mg	Series II 1/10/20 mg	Series 0 0,01/0,1/1 mg	0,0001 mg	0,001 mg	0,01 mg	0,1 mg	1 mg	2 mg	5 mg	10 mg	20 mg
ISCADOR M	● ● ●	● ● ●	● ● ●	● ●	● ●	● ●	●	●	● ●			● ● ●	● ● ●
ISCADOR M c. Arg. <sup>1</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR M c. Cu <sup>2</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR M c. Hg <sup>3</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR M spezial <sup>4</sup>									●	●	●		
ISCADOR Qu	● ● ●	● ● ●	● ● ●	● ●	● ●	● ●	●	●	● ●			● ● ●	● ● ●
ISCADOR Qu c. Arg. <sup>1</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR Qu c. Cu <sup>2</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR Qu c. Hg <sup>3</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR Qu spezial <sup>4</sup>									●	●	●		
ISCADOR P	● ● ●	● ● ●	● ● ●	● ●	● ●	● ●	●	●	● ●		●	● ● ●	● ● ●
ISCADOR P c. Hg <sup>3</sup>	●	● ●	● ●				●	●	● ●			● ●	● ●
ISCADOR A	●	●	●				●	●	●			●	●
ISCADOR U c. Hg <sup>3</sup>	● ● ●	● ● ●	● ● ●				● ●	● ●	● ●			● ● ●	● ● ●

● Swiss product range

● German product range

● International product range

(Metal addition of 0.0002 parts as

titration in a D4 dilution)

<sup>1</sup> as silver carbonate

<sup>2</sup> as copper carbonate

<sup>3</sup> as mercury sulphate

<sup>4</sup> with constant quantity of mistletoe lectins

Product range may vary depending on applicable laws and regulations.

## Studies

A large number of clinical studies on the treatment of various tumour entities with ISCADOR is available. Almost all studies show an advantage for ISCADOR, which is associated particularly with improved quality of life, reduction of disease- or therapy-related symptoms and alleviation of tumour- or therapy-related fatigue. Furthermore, a survival advantage was found with ISCADOR. Two meta-analyses from 2020 on the influence of mistletoe therapy on quality of life and on survival, respectively, were able to confirm these findings <sup>[1, 2]</sup>. Due to their high quality, the studies by Tröger et al. on breast and pancreatic carcinoma were particularly highlighted in these meta-analyses <sup>[3-7]</sup>.

In the randomized study on breast carcinoma, supplementary mistletoe therapy with ISCADOR significantly improved the quality of life of patients during chemotherapy with CAF. In addition, ISCADOR improved the tolerability of chemotherapy, and there were fewer treatment discontinuations, dose changes and delays in conventional therapy. The ISCADOR group also showed a reduced incidence of chemotherapy-induced neutropenia <sup>[3, 4, 5]</sup>. In the randomized phase III-study on patients with locally advanced or metastatic pancreatic cancer, patients receiving ISCADOR showed a significant and clinically relevant advantage in overall survival and a considerable improvement in quality of life <sup>[6, 7]</sup>.

1. Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. *BMC Complementary Medicine and Therapies* 2020;20:227
2. Ostermann T, Appelbaum S, Poier D, et al. A systematic review and meta-analysis on the survival of cancer patients treated with a fermented *Viscum album* L. extract (Iscador): An update of findings. *Complement Med Res* 2020;27:260-271
3. Tröger W, Jezdic S, Zdrle Z, et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. *Breast Cancer*, 2009;16:35-45
4. Tröger W, Zdrle Z, Stankovic N, Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with *Viscum album* (L.) extract to chemotherapy alone. *Breast Cancer (Auckl)*, 2012;6:173-180
5. Pelzer F, Tröger W, Nat DR. Complementary treatment with mistletoe extracts during chemotherapy: safety, neutropenia, fever, and quality of life assessed in a randomized study. *J Altern Complement Med*, 2018;24:954-961
6. Tröger W, Galun D, Reif M, et al. *Viscum album* [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. *Eur J Cancer*, 2013;49:3788-3797
7. Tröger W, Galun D, Reif M, et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. *Dtsch Arztebl Int*, 2014;111:493-502



## Reimbursement

In Switzerland, basic insurance covers mistletoe therapy when prescribed by a medical doctor with a specialisation suitable to treat the underlying condition or respective symptoms.

In Germany, health insurance funds reimburse the costs of anthroposophical mistletoe therapy if the mistletoe preparation is prescribed as a part of palliative tumour therapy to improve the quality of life. Anthroposophical mistletoe preparations can also be prescribed as part of curative cancer therapy under health insurance coverage, if they are used to reduce serious side effects occurring when an approved and available drug is used as intended. In this case, the observed side effects must cause health disorders impairing the quality of life considerably, e.g. as cancer-related fatigue.

---

## *Personal consultation*



If you have any further questions regarding reimbursement, please contact our Infoline for medical professionals: [www.iscador.com/contact](http://www.iscador.com/contact)

---






# Aqueous mistletoe solution for oral use:

## Viscum album praeparatum

The aqueous mistletoe drops for oral administration are authorised in Switzerland as anthroposophical medicinal product without indication (dispensing category D).

Drops for oral use are available from mistletoe collected from apple tree (Malus), pine (Pinus), and oak (Quercus), respectively.

The drops for oral use are available without prescription at medicinal suppliers in Switzerland.

Viscum album praeparatum*			
Drops for oral use			
Mistletoe harvested from host tree	Product	Bottles à 20 ml	
		0.1 %	3 %
 Malus (Apple tree)	Viscum Mali praeparatum		•
 Pinus (Pine)	Viscum Pini praeparatum	•	•
 Quercus (Oak)	Viscum Quercus praeparatum	•	•

\* Drug without indication



# Mistletoe cream: *Viscum album* Herba Extractum resinosum 10%

A lot of research was necessary to make the fat-soluble components of the mistletoe available in a medicinal product for the first time. The base is a resinuous, glue-like substance derived from the green parts of the plant. A newly developed CO<sub>2</sub>-extraction process enabled us to extract this «mistletoe glue» from pine mistletoe and further process it into a cream.

Extracts from pine mistletoe are versatile and, e.g., due to their relation to the skin, ideal for the production of a cream.

Experience <sup>1,2</sup> has shown that «*Viscum album* Herba Extractum resinosum 10%, Cream» may be used for topical therapy of precancerous lesions and some malignant lesions of the skin.

The cream is approved in Switzerland as an anthroposophical medicine without indication and available on prescription in 5g tubes.



1. Kunz C et al. Topische Behandlung des Basalzellkarzinoms mit VISCUM ALBUM, lipophiler Extrakt 10%, Unguentum – Eine Fallserie-Studie. In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, Matthes H, Schilcher H, Stange R (Hrsg.) Die Mistel in der Tumorthherapie 3 – Aktueller Stand der Forschung und klinische Anwendung. KVC-Verlag, Essen 2013, 315-322
2. Urech K et al. Indikationsspektrum und Wirkungen der topischen Behandlung von Hautläsionen mit *Viscum album*, Resina 10 %, Unguentum – Eine retrospektive Fallserie-Studie (Indications, effects and adverse drug reactions of the topical treatment of skin lesions with *Viscum album*, Resina 10 %, Unguentum – A retrospective case series study). In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, Matthes H, Schilcher H, Spahn G, Stange R (Hrsg.) Die Mistel in der Tumorthherapie 4. Aktueller Stand der Forschung und klinische Anwendung. KVC Verlag, Essen 2016, 419-428

# Icelandic moss solution for injection:

## Cetraria praeparata

The lichen «Icelandic moss» (lat. *Cetraria islandica*) has a long history as a remedy for inflammations of the skin, mucous membranes and the respiratory tract. In addition to its anti-irritant and anti-inflammatory properties, it has been used in integrative cancer treatment for many years to support and augment the benefits of mistletoe therapy.

The injection solution Cetraria praeparata is approved in Switzerland as an anthroposophical remedy without indication and is available on prescription.

Cetraria praeparata is injected subcutaneously two to three times a week. In the beginning, low concentrations are used, which, if well tolerated, can be increased. Both rhythmically changing dosage as well as continuous treatment with unchanging doses are possible.

In principle, the duration of application is not limited. It depends on the individual progression of the disease and the personal condition or findings of the patient and is defined by the attending therapist.

Cetraria praeparata*				
Injection solution s.c.				
Plant	Product	Ampoules à 1 ml		
		0.01 %	0.1 %	1 %
Cetraria islandica (Icelandic moss)	Cetraria praeparata	•	•	•

\* Drug without indication



# We are here for you

## Infoline for medical professionals

Our qualified staff assists you with therapy recommendations or with developing an individual solution for your patients. Whether you have questions about ISCADOR or one of our other preparations, our team is at your service.

E-mail: [infoline@iscador.com](mailto:infoline@iscador.com)

---

### Phone (free of charge):

CH: 0800 706 700

DE: 0800 706 70 00

AT, FR, IT, NZ, SE, UK: 00800 706 70000

---

All other countries: +49 7621 162 26 00

## Client advisors

Our client advisors in Switzerland and Germany personally support you with training, material requirements or additional information. Contact us to get in touch with them: [www.iscador.com/contact](http://www.iscador.com/contact)

---

## *Did you know ...*



... that patients can administer mistletoe injections themselves? With our brochure «Application» for patients you can help them to prepare for self-injections. Or show them the instruction video on our website:  
[www.iscador.com/application](http://www.iscador.com/application)

---

## Drug information for Switzerland:

**ISCADOR® active ingredient:** fermented aqueous extract from the fresh mistletoe plant (*Viscum album* L.) from various host trees; sometimes with an addition of metallic salt

**Indication:** Supplementary treatment for malignant and benign tumour diseases

**Application:** for subcutaneous injection (s.c.)

**Contraindications:** Allergy to mistletoe preparations; Temperatures > 38°C; chronic granulomatous diseases, florid autoimmune diseases and those under immunosuppressive therapy; hyperthyroidism

**Undesirable side effects:** Allergic or allergoid reactions may occur; general allergic (anaphylactic) reactions with Quincke oedema, chills, shortness of breath, bronchospasm and shock are observed rarely, in this case emergency anti-allergy treatment should be carried out and the preparation should be discontinued.

**Interactions:** No studies have been carried out on interactions.

**Submission category:** B

**Further information:** see information for healthcare professionals at [www.swissmedinfo.ch](http://www.swissmedinfo.ch)

Isador AG, Kirschweg 9, 4144 Arlesheim

## Drug information for Germany:

**ISCADOR® solution for injections.**

**Active ingredient:** fermented, aqueous mistletoe extract.

**Composition:** fermented, aqueous extract from *Viscum album* from various host trees.

**Other ingredients:** sodium chloride and water for injection.

**Indications:** according to the anthroposophic understanding of human being and nature. This includes in adults: in malignant tumours, also with accompanying impairment of haematopoietic organs; in benign tumours; in defined precancerous disorders; for prevention of tumour recurrence after surgery.

**Contraindications:** known allergy to preparations of European mistletoe (*Viscum album* L.).

Disorders accompanied by acute inflammation or high fever. Chronic granulomatous diseases, florid autoimmune diseases, and diseases treated with immunosuppressive drugs. Hyperthyroidism with tachycardia.

**Side effects:** locally restricted inflammatory reactions around the subcutaneous injection site, fever, flu-like symptoms, swellings of regional lymph nodes as well as activation of inflammations/allergic reactions. The occurrence of chronic granulomatous inflammation, autoimmune diseases and symptoms of an increase in brain pressure in brain tumors/metastases during mistletoe therapy have also been reported.

**Pharmaceutical forms and packs:** solution for injection in series packs: 2 x 7 ampoules cont. 1 ml (bundle package), series 0 also 1 x 7 ampoules cont. 1 ml. Solution for injection in single strength packs: 1 x 7 ampoules cont. 1 ml, Iscador special also 2 x 7 ampoules cont. 1 ml (bundle package).  
Isador AG, Spitalstr. 22, 79539 Lörrach.

## Publication details

© Isador AG

## Note

This brochure is protected by copyright. Reprinting, inclusion in online services and on the internet as well as reproduction on data storage media – including extracts – is allowed exclusively with prior written approval of Isador AG.

Great care has been taken in compiling the information and recommendations contained in this document to ensure they are in line with the current state of knowledge. Errors and misprints are reserved. Guarantee and liability claims of any kind are excluded.

For better readability, the masculine form is used throughout.



## **Headquarters in Switzerland**

Iscador AG  
Kirschweg 9  
4144 Arlesheim  
Switzerland

Phone +41 (0)61 706 72 22  
Fax +41 (0)61 706 72 33

info@iscador.ch  
www.iscador.ch

## **Branch office in Germany**

Iscador AG  
Spitalstraße 22  
79539 Lörrach  
Germany

Phone +49 (0)7621 162 26 00  
Fax +49 (0)7621 162 26 01

info@iscador.de  
www.iscador.de

## **Infoline for medical professionals & Pharmacovigilance**

### **Switzerland and Principality of Liechtenstein**

Phone 0800 706 700  
Fax +41 (0)61 706 75 33  
E-mail infoline@iscador.ch

### **Germany**

Phone 0800 706 70 00  
Fax +49 (0)7621 162 26 02  
E-mail infoline@iscador.de

### **International (AT/FR/IT/NZ/SE/UK)**

Phone 00800 706 700 00  
E-mail infoline@iscador.com

Please find further information and our  
hours of operation on our web-site.